Mirum Pharmaceuticals, Inc. Operating Lease, Right-of-Use Asset, Amortization Expense
Mirum Pharmaceuticals, Inc. (MIRM) reported Operating Lease, Right-of-Use Asset, Amortization Expense of $144.00 thousand for the 3-month period ending 2023-03-31, per its 10-Q filed 2023-05-04.
Discontinued › Cash Flow › Operating Activities
us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense · last filed 2023-05-04
- Mirum Pharmaceuticals, Inc. operating lease, right-of-use asset, amortization expense for the quarter ending 2023-03-31 was $144.00K, a 42.57% increase year-over-year.
- Mirum Pharmaceuticals, Inc. operating lease, right-of-use asset, amortization expense for the quarter ending 2022-12-31 was $128.00K, a 34.74% increase year-over-year.
- Mirum Pharmaceuticals, Inc. operating lease, right-of-use asset, amortization expense for the quarter ending 2022-09-30 was $108.00K, a 14.89% increase year-over-year.
- Mirum Pharmaceuticals, Inc. operating lease, right-of-use asset, amortization expense for the quarter ending 2022-06-30 was $106.00K, a 10.42% increase year-over-year.
- Mirum Pharmaceuticals, Inc. operating lease, right-of-use asset, amortization expense for fiscal 2022 was $443.00K, a 16.58% increase from fiscal 2021.
- Mirum Pharmaceuticals, Inc. operating lease, right-of-use asset, amortization expense for fiscal 2021 was $380.00K.
| Period end | Operating Lease, Right-of-Use Asset, Amortization Expense 3 month | Operating Lease, Right-of-Use Asset, Amortization Expense 6 month | Operating Lease, Right-of-Use Asset, Amortization Expense 9 month | Operating Lease, Right-of-Use Asset, Amortization Expense 12 month |
|---|---|---|---|---|
| 2023-03-31 | $144.00K 10-Q · filed 2023-05-04 | $272.00K derived: sum of 2 quarters · filed 2023-05-04 | $380.00K derived: sum of 3 quarters · filed 2023-05-04 | $486.00K derived: sum of 4 quarters · filed 2023-05-04 |
| 2022-12-31 | $128.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-08 | $236.00K derived: sum of 2 quarters · filed 2023-03-08 | $342.00K derived: sum of 3 quarters · filed 2023-03-08 | $443.00K 10-K · filed 2023-03-08 |
| 2022-09-30 | $108.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-09 | $214.00K derived: sum of 2 quarters · filed 2022-11-09 | $315.00K 10-Q · filed 2022-11-09 | $410.00K derived: sum of 4 quarters · filed 2023-05-04 |
| 2022-06-30 | $106.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-04 | $207.00K 10-Q · filed 2022-08-04 | $302.00K derived: sum of 3 quarters · filed 2023-05-04 | $396.00K derived: sum of 4 quarters · filed 2023-05-04 |
| 2022-03-31 | $101.00K 10-Q · filed 2023-05-04 | $196.00K derived: sum of 2 quarters · filed 2023-05-04 | $290.00K derived: sum of 3 quarters · filed 2023-05-04 | $386.00K derived: sum of 4 quarters · filed 2023-05-04 |
| 2021-12-31 | $95.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-08 | $189.00K derived: sum of 2 quarters · filed 2023-03-08 | $285.00K derived: sum of 3 quarters · filed 2023-03-08 | $380.00K 10-K · filed 2023-03-08 |
| 2021-09-30 | $94.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-09 | $190.00K derived: sum of 2 quarters · filed 2022-11-09 | $285.00K 10-Q · filed 2022-11-09 | |
| 2021-06-30 | $96.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-04 | $191.00K 10-Q · filed 2022-08-04 | ||
| 2021-03-31 | $95.00K 10-Q · filed 2022-05-05 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Travere Therapeutics, Inc. (TVTX) | United States | $5.712B | -123.10 |
| Oruka Therapeutics, Inc. (ORKA) | United States | $5.663B | -43.76 |
| Cogent Biosciences, Inc. (COGT) | United States | $5.450B | -17.61 |
| Gossamer Bio, Inc. (GOSS) | United States | $5.355B | -0.65 |
| Amneal Pharmaceuticals, Inc. (AMRX) | $6.326B | 25.62 | |
| Liquidia Corp (LQDA) | United States | $6.347B | 51.23 |
| PTC THERAPEUTICS, INC. (PTCT) | United States | $5.199B | -177.07 |
| Dianthus Therapeutics, Inc. /DE/ (DNTH) | United States | $5.082B | -27.79 |
| Erasca, Inc. (ERAS) | United States | $5.073B | -19.96 |
| Veradermics, Inc (MANE) | United States | $4.839B |